Danaher Corporation

BUL:DAP Rapport sur les actions

Capitalisation boursière : €174.0b

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Danaher Résultats passés

Passé contrôle des critères 2/6

Danaher has been growing earnings at an average annual rate of 13.1%, while the Life Sciences industry saw earnings growing at 16.5% annually. Revenues have been growing at an average rate of 7.1% per year. Danaher's return on equity is 8.1%, and it has net margins of 17.2%.

Informations clés

13.1%

Taux de croissance des bénéfices

12.4%

Taux de croissance du BPA

Life Sciences Croissance de l'industrie14.2%
Taux de croissance des recettes7.1%
Rendement des fonds propres8.1%
Marge nette17.2%
Dernière mise à jour des bénéfices28 Jun 2024

Mises à jour récentes des performances passées

Recent updates

Ventilation des recettes et des dépenses

Comment Danaher gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.

Historique des gains et des recettes

BUL:DAP Recettes, dépenses et bénéfices (USD Millions )
DateRecettesLes revenusDépenses G+ADépenses de R&D
28 Jun 2423,5684,0567,3581,528
29 Mar 2423,7374,0697,2811,498
31 Dec 2323,8904,2007,2451,503
29 Sep 2322,2754,5976,4911,387
30 Jun 2323,0655,0196,4891,390
31 Mar 2324,9045,7576,7621,460
31 Dec 2226,6436,2227,0801,528
30 Sep 2231,2506,6408,5721,787
01 Jul 2230,8166,2068,4891,808
01 Apr 2230,2836,2068,3691,803
31 Dec 2124,8025,2836,7631,498
01 Oct 2128,0655,6367,8181,643
02 Jul 2126,7205,3617,5431,544
02 Apr 2124,7994,5957,2781,441
31 Dec 2022,2843,5106,8801,348
02 Oct 2020,3923,0836,3541,246
03 Jul 2018,8862,8535,9541,186
03 Apr 2018,0342,6145,6591,146
31 Dec 1917,9112,3645,5771,126
27 Sep 1915,5622,0934,709980
28 Jun 1916,0372,1454,880998
29 Mar 1916,5732,1665,1251,028
31 Dec 1817,0492,4065,3561,059
28 Sep 1819,6152,7616,2461,211
29 Jun 1819,2902,6696,1731,189
30 Mar 1818,8192,5536,0721,160
31 Dec 1715,5192,1725,012956
29 Sep 1717,8282,3605,7641,098
30 Jun 1717,4322,1915,6331,060
31 Mar 1717,1642,0515,5361,016
31 Dec 1616,8822,1535,481975
30 Sep 1616,6211,9275,362943
01 Jul 1616,0011,9055,218914
01 Apr 1613,6631,7754,549788
31 Dec 1514,4341,7474,635861
02 Oct 1515,3351,8754,769926
03 Jul 1516,5302,1774,8651,002
03 Apr 1519,1862,5215,3481,143
31 Dec 1412,8671,6393,953769
26 Sep 1419,1972,6835,3051,189
27 Jun 1419,1592,5995,3111,210
28 Mar 1419,3362,5835,4051,267
31 Dec 1318,2832,5915,0421,104
27 Sep 1318,8272,5365,3481,212

Des revenus de qualité: DAP has high quality earnings.

Augmentation de la marge bénéficiaire: DAP's current net profit margins (17.2%) are lower than last year (21.8%).

Analyse des flux de trésorerie disponibles par rapport aux bénéfices

Analyse de la croissance passée des bénéfices

Tendance des revenus: DAP's earnings have grown by 13.1% per year over the past 5 years.

Accélération de la croissance: DAP's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Bénéfices par rapport au secteur d'activité: DAP had negative earnings growth (-19.4%) over the past year, making it difficult to compare to the Life Sciences industry average (-13%).

Rendement des fonds propres

ROE élevé: DAP's Return on Equity (8.1%) is considered low.

Rendement des actifs

Rendement des capitaux employés

Découvrir des entreprises performantes dans le passé

7D

1Y

7D

1Y

7D

1Y